CAS: 2381037-82-5

RBN-2397 is a potent, selective and orally active accross species NAD+ competitive PARP7 inhibitor with IC50 less than 3 nM.

RBN-2397

RBN-2397 is a poly-adp-ribose polymerase inhibitor that has been shown to have clinical efficacy in the treatment of cancer. RBN-2397 is a molecule that inhibits the activity of poly-adp-ribose polymerase (PARP), an enzyme involved in the homologous recombination repair of DNA. This inhibition leads to DNA damage and cell death by apoptosis, which are associated with tumor development and progression. RBN-2397 has been shown to be effective as an adjunct therapy for people with metastatic melanoma or other cancers who are resistant to interferon alfa-2b and cytosolic colony stimulating factor.

(S)-5-((1-(3-Oxo-3-(4-(5-(Trifluoromethyl)Pyrimidin-2-Yl)Piperazin-1-Yl)Propoxy)Propan-2-Yl)Amino)-4-(Trifluoromethyl)Pyridazin-3(2H)-One